BILLINGHAM, England, June 12 /PRNewswire/ -- Avecia Biotechnology has received a US$3.9m grant from the US Government to develop a version of Thraxine (TM), an rPA (recombinant Protective Antigen)-based anthrax vaccine, with increased stability. Due for Completion by April 2008, and using leading-edge technologies, the programme aims to develop a version of Thraxine (TM) that can be stored, transported and used without the need for a conventional cold chain.
